{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T15:30:22Z","timestamp":1795015822061,"version":"4.10.1"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006671","name":"Maryland Department of Health and Mental Hygiene","doi-asserted-by":"publisher","award":["CH-649-CRF"],"award-info":[{"award-number":["CH-649-CRF"]}],"id":[{"id":"10.13039\/100006671","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R21CA297125"],"award-info":[{"award-number":["R21CA297125"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA042014"],"award-info":[{"award-number":["P30CA042014"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA042014"],"award-info":[{"award-number":["P30CA042014"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA042014"],"award-info":[{"award-number":["P30CA042014"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["DBG-25-1434942-01-ET"],"award-info":[{"award-number":["DBG-25-1434942-01-ET"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI095190"],"award-info":[{"award-number":["AI095190"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["GM145313"],"award-info":[{"award-number":["GM145313"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chimeric antigen receptor (CAR) T-cell therapy has shown remarkable efficacy in cancer treatment. Nevertheless, most patients receiving CAR T cells relapse within 5 years of treatment. CAR-mediated trogocytosis (CMT) is a potential tumor escape mechanism in which cell surface proteins transfer from tumor cells to CAR T cells. CMT results in the emergence of antigen-negative tumor cells, which can evade future CAR detection, and antigen-positive CAR T cells, which have been suggested to cause CAR T-cell fratricide and exhaustion. Whether CMT indeed causes CAR T-cell dysfunction and the molecular mechanisms conferring CMT remain unknown. Using a selective degrader of trogocytosed antigen in CAR T cells, we show that the presence of trogocytosed antigen on the CAR T-cell surface directly causes CAR T-cell fratricide and exhaustion. By performing small molecule screening using a custom high-throughput CMT screening assay, we found that the cysteine protease cathepsin B is essential for CMT and that inhibition of cathepsin B is sufficient to prevent CAR T-cell fratricide and exhaustion, leading to improved long-term in vitro and in vivo CAR T-cell persistence and in vitro antitumor activity. Our data demonstrate that it is feasible to separate CMT from cytotoxic activity, that CAR T-cell persistence, a key factor associated with clinical CAR T-cell efficacy, is directly linked to cathepsin B activity in CAR T cells, and that it is possible to improve CAR T-cell function through selective inhibition of CMT.<\/jats:p>","DOI":"10.1038\/s41392-026-02654-z","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T06:54:55Z","timestamp":1776840895000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Preventing trogocytosis by cathepsin B inhibition augments CAR T-cell function"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8069-0210","authenticated-orcid":false,"given":"Kenneth A.","family":"Dietze","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiet","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aashli","family":"Pathni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Fazekas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxiang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan","family":"Rosati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5935-8339","authenticated-orcid":false,"given":"Jillian M.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maday","family":"Galeana Figueroa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etse","family":"Gebru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Yamoah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rediet","family":"Mulatu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron P.","family":"Rapoport","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0159-8724","authenticated-orcid":false,"given":"David H.","family":"Lum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0501-771X","authenticated-orcid":false,"given":"Xiaoxuan","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabarinath V.","family":"Radhakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4747-488X","authenticated-orcid":false,"given":"Djordje","family":"Atanackovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arpita","family":"Upadhyaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7085-9027","authenticated-orcid":false,"given":"Tim","family":"Luetkens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"key":"2654_CR1","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1016\/j.cell.2017.12.002","volume":"171","author":"M Sadelain","year":"2017","unstructured":"Sadelain, M. CD19 CAR T Cells. Cell 171, 1471 (2017).","journal-title":"Cell"},{"key":"2654_CR2","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude, S. L. et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl. J. Med. 378, 439\u2013448 (2018).","journal-title":"N. Engl. J. Med."},{"key":"2654_CR3","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/nature22395","volume":"545","author":"M Sadelain","year":"2017","unstructured":"Sadelain, M., Rivi\u00e8re, I. & Riddell, S. Therapeutic T cell engineering. Nature 545, 423\u2013431 (2017).","journal-title":"Nature"},{"key":"2654_CR4","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","volume":"380","author":"N Raje","year":"2019","unstructured":"Raje, N. et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N. Engl. J. Med. 380, 1726\u20131737 (2019).","journal-title":"N. Engl. J. Med."},{"key":"2654_CR5","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41375-019-0669-4","volume":"34","author":"M D\u2019Agostino","year":"2020","unstructured":"D\u2019Agostino, M. & Raje, N. Anti-BCMA CAR T-cell therapy in multiple myeloma: Can we do better? Leukemia 34, 21\u201334 (2020).","journal-title":"Leukemia"},{"key":"2654_CR6","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1111\/jcmm.12810","volume":"20","author":"A Romanski","year":"2016","unstructured":"Romanski, A. et al. CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies. J. Cell. Mol. Med. 20, 1287\u20131294 (2016).","journal-title":"J. Cell. Mol. Med."},{"key":"2654_CR7","doi-asserted-by":"publisher","first-page":"e26527","DOI":"10.4161\/onci.26527","volume":"2","author":"L Boissel","year":"2013","unstructured":"Boissel, L. et al. Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity. OncoImmunology 2, e26527 (2013).","journal-title":"OncoImmunology"},{"key":"2654_CR8","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell, K. M. & Kochenderfer, J. N. Long-term outcomes following CAR T cell therapy: what we know so far. Nat. Rev. Clin. Oncol. 20, 359\u2013371 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2654_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40291-025-00771-z","volume":"29","author":"A Lee","year":"2025","unstructured":"Lee, A. Obecabtagene autoleucel: first approval. Mol. Diagn. Ther. 29, 1\u20135 (2025).","journal-title":"Mol. Diagn. Ther."},{"key":"2654_CR10","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1634\/theoncologist.2018-0490","volume":"24","author":"A Purdum","year":"2019","unstructured":"Purdum, A., Tieu, R., Reddy, S. R. & Broder, M. S. Direct costs associated with relapsed diffuse large B-cell lymphoma therapies. Oncologist 24, 1229\u20131236 (2019).","journal-title":"Oncologist"},{"key":"2654_CR11","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1080\/10428194.2021.1975188","volume":"63","author":"G Kanas","year":"2022","unstructured":"Kanas, G. et al. Epidemiology of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) in the United States and Western Europe: population-level projections for 2020\u20132025. Leuk. Lymphoma 63, 54\u201363 (2022).","journal-title":"Leuk. Lymphoma"},{"key":"2654_CR12","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1182\/bloodadvances.2020003482","volume":"6","author":"P Grover","year":"2022","unstructured":"Grover, P. et al. Chimeric antigen receptor T-cell therapy in adults with B-cell acute lymphoblastic leukemia. Blood Adv. 6, 1608\u20131618 (2022).","journal-title":"Blood Adv."},{"key":"2654_CR13","first-page":"349","volume":"140","author":"WA Bethge","year":"2022","unstructured":"Bethge, W. A. et al. GLA\/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany. Blood 140, 349\u2013358 (2022).","journal-title":"Blood"},{"key":"2654_CR14","doi-asserted-by":"publisher","first-page":"3382","DOI":"10.1038\/s41375-020-0831-z","volume":"34","author":"J Pan","year":"2020","unstructured":"Pan, J. et al. Frequent occurrence of CD19-negative relapse after CD19 CAR T and consolidation therapy in 14 TP53-mutated r\/r B-ALL children. Leukemia 34, 3382\u20133387 (2020).","journal-title":"Leukemia"},{"key":"2654_CR15","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1182\/blood.2020009515","volume":"138","author":"K Wudhikarn","year":"2021","unstructured":"Wudhikarn, K. et al. Interventions and outcomes of adult patients with B-ALL progressing after CD19 chimeric antigen receptor T-cell therapy. Blood 138, 531\u2013543 (2021).","journal-title":"Blood"},{"key":"2654_CR16","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1172\/JCI125423","volume":"129","author":"OC Finney","year":"2019","unstructured":"Finney, O. C. et al. CD19 CAR T cell product and disease attributes predict leukemia remission durability. J. Clin. Invest. 129, 2123\u20132132 (2019).","journal-title":"J. Clin. Invest."},{"key":"2654_CR17","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41591-018-0290-5","volume":"25","author":"J Feucht","year":"2019","unstructured":"Feucht, J. et al. Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency. Nat. Med. 25, 82\u201388 (2019).","journal-title":"Nat. Med."},{"key":"2654_CR18","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude, S. L. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507\u20131517 (2014).","journal-title":"N. Engl. J. Med."},{"key":"2654_CR19","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.ccell.2015.09.004","volume":"28","author":"Z Zhao","year":"2015","unstructured":"Zhao, Z. et al. Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells. Cancer Cell 28, 415\u2013428 (2015).","journal-title":"Cancer Cell"},{"key":"2654_CR20","first-page":"372","volume":"16","author":"NN Shah","year":"2019","unstructured":"Shah, N. N. & Fry, T. J. Mechanisms of resistance to CAR T cell therapy. Nat. Rev. Clin. Oncol. 16, 372\u2013385 (2019).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2654_CR21","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","volume":"129","author":"RA Gardner","year":"2017","unstructured":"Gardner, R. A. et al. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood 129, 3322\u20133331 (2017).","journal-title":"Blood"},{"key":"2654_CR22","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41586-019-1054-1","volume":"568","author":"M Hamieh","year":"2019","unstructured":"Hamieh, M. et al. CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape. Nature 568, 112\u2013116 (2019).","journal-title":"Nature"},{"key":"2654_CR23","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1038\/s41375-022-01585-2","volume":"36","author":"ML Olson","year":"2022","unstructured":"Olson, M. L. et al. Low-affinity CAR T cells exhibit reduced trogocytosis, preventing rapid antigen loss, and increasing CAR T cell expansion. Leukemia 36, 1943\u20131946 (2022).","journal-title":"Leukemia"},{"key":"2654_CR24","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/s41591-022-02003-x","volume":"28","author":"Y Li","year":"2022","unstructured":"Li, Y. et al. KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape. Nat. Med. 28, 2133\u20132144 (2022).","journal-title":"Nat. Med."},{"key":"2654_CR25","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/cmi.2008.32","volume":"5","author":"KA Ahmed","year":"2008","unstructured":"Ahmed, K. A., Munegowda, M. A., Xie, Y. & Xiang, J. Intercellular trogocytosis plays an important role in modulation of immune responses. Cell. Mol. Immunol. 5, 261\u2013269 (2008).","journal-title":"Cell. Mol. Immunol."},{"key":"2654_CR26","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1126\/science.286.5441.952","volume":"286","author":"J-F Huang","year":"1999","unstructured":"Huang, J.-F. et al. TCR-mediated internalization of peptide-MHC complexes acquired by T cells. Science 286, 952\u2013954 (1999).","journal-title":"Science"},{"key":"2654_CR27","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.add7900","volume":"15","author":"ERV Mause","year":"2023","unstructured":"Mause, E. R. V. et al. Systematic single amino acid affinity tuning of CD229 CAR T cells retains efficacy against multiple myeloma and eliminates on-target off-tumor toxicity. Sci. Transl. Med. 15, eadd7900 (2023).","journal-title":"Sci. Transl. Med."},{"key":"2654_CR28","doi-asserted-by":"publisher","first-page":"e005091","DOI":"10.1136\/jitc-2022-005091","volume":"10","author":"N Camviel","year":"2022","unstructured":"Camviel, N. et al. Both APRIL and antibody-fragment-based CAR T cells for myeloma induce BCMA downmodulation by trogocytosis and internalization. J. Immunother. Cancer 10, e005091 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"2654_CR29","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1172\/JCI126397","volume":"129","author":"AD Cohen","year":"2019","unstructured":"Cohen, A. D. et al. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. J. Clin. Investig. 129, 2210\u20132221 (2019).","journal-title":"J. Clin. Investig."},{"key":"2654_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-14619-z","volume":"11","author":"SV Radhakrishnan","year":"2020","unstructured":"Radhakrishnan, S. V. et al. CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide. Nat. Commun. 11, 798 (2020).","journal-title":"Nat. Commun."},{"key":"2654_CR31","doi-asserted-by":"publisher","unstructured":"Morales, E. A. et al. Restricting CAR T cell trafficking expands targetable antigen space. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2024.02.08.579002 (2024).","DOI":"10.1101\/2024.02.08.579002"},{"key":"2654_CR32","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/s41586-022-05235-6","volume":"610","author":"H Marei","year":"2022","unstructured":"Marei, H. et al. Antibody targeting of E3 ubiquitin ligases for receptor degradation. Nature 610, 182\u2013189 (2022).","journal-title":"Nature"},{"key":"2654_CR33","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","volume":"21","author":"M B\u00e9k\u00e9s","year":"2022","unstructured":"B\u00e9k\u00e9s, M., Langley, D. R. & Crews, C. M. PROTAC targeted protein degraders: the past is prologue. Nat. Rev. Drug Discov. 21, 181\u2013200 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2654_CR34","doi-asserted-by":"publisher","first-page":"10891","DOI":"10.3390\/ijms241310891","volume":"24","author":"M Billerhart","year":"2023","unstructured":"Billerhart, M. et al. Recombinant human CD19 in CHO-K1 cells: glycosylation patterns as a quality attribute of high yield processes. Int. J. Mol. Sci. 24, 10891 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"2654_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31035-7","volume":"13","author":"A Heard","year":"2022","unstructured":"Heard, A. et al. Antigen glycosylation regulates efficacy of CAR T cells targeting CD19. Nat. Commun. 13, 3367 (2022).","journal-title":"Nat. Commun."},{"key":"2654_CR36","doi-asserted-by":"publisher","first-page":"7556","DOI":"10.4049\/jimmunol.172.12.7556","volume":"172","author":"SR Brooks","year":"2004","unstructured":"Brooks, S. R., Kirkham, P. M., Freeberg, L. & Carter, R. H. Binding of cytoplasmic proteins to the CD19 intracellular domain is high affinity, competitive, and multimeric. J. Immunol. 172, 7556\u20137564 (2004).","journal-title":"J. Immunol."},{"key":"2654_CR37","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1038\/s41591-018-0201-9","volume":"24","author":"M Ruella","year":"2018","unstructured":"Ruella, M. et al. Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nat. Med. 24, 1499\u20131503 (2018).","journal-title":"Nat. Med."},{"key":"2654_CR38","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1021\/acschembio.5b00753","volume":"11","author":"AS Dixon","year":"2016","unstructured":"Dixon, A. S. et al. NanoLuc complementation reporter optimized for accurate measurement of protein interactions in cells. ACS Chem. Biol. 11, 400\u2013408 (2016).","journal-title":"ACS Chem. Biol."},{"key":"2654_CR39","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1073\/pnas.1615973114","volume":"114","author":"K Miyake","year":"2017","unstructured":"Miyake, K. et al. Trogocytosis of peptide-MHC class II complexes from dendritic cells confers antigen-presenting ability on basophils. Proc. Natl. Acad. Sci. USA 114, 1111\u20131116 (2017).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2654_CR40","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1093\/infdis\/jiz671","volume":"221","author":"AA Gilmartin","year":"2020","unstructured":"Gilmartin, A. A., Ralston, K. S. & Petri, W. A. Inhibition of amebic cysteine proteases blocks amebic trogocytosis but not phagocytosis. J. Infect. Dis. 221, 1734\u20131739 (2020).","journal-title":"J. Infect. Dis."},{"key":"2654_CR41","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.3390\/cells10061478","volume":"10","author":"J Reed","year":"2021","unstructured":"Reed, J., Reichelt, M. & Wetzel, S. A. Lymphocytes and trogocytosis-mediated signaling. Cells 10, 1478 (2021).","journal-title":"Cells"},{"key":"2654_CR42","doi-asserted-by":"publisher","first-page":"3637","DOI":"10.4049\/jimmunol.178.6.3637","volume":"178","author":"D Hudrisier","year":"2007","unstructured":"Hudrisier, D., Aucher, A., Puaux, A.-L., Bordier, C. & Joly, E. Capture of target cell membrane components via trogocytosis is triggered by a selected set of surface molecules on T or B cells. J. Immunol. 178, 3637\u20133647 (2007).","journal-title":"J. Immunol."},{"key":"2654_CR43","first-page":"A000508","volume":"2011","author":"D Cavallo-Medved","year":"2011","unstructured":"Cavallo-Medved, D., Moin, K. & Sloane, B. Cathepsin B. AFCS Nat. Mol. Pages 2011, A000508 (2011).","journal-title":"AFCS Nat. Mol. Pages"},{"key":"2654_CR44","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/S1357-2725(96)00152-5","volume":"29","author":"JS Mort","year":"1997","unstructured":"Mort, J. S. & Buttle, D. J. Cathepsin B. Int. J. Biochem. Cell Biol. 29, 715\u2013720 (1997).","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"2654_CR45","doi-asserted-by":"publisher","first-page":"264","DOI":"10.3390\/cells8030264","volume":"8","author":"E Vidak","year":"2019","unstructured":"Vidak, E., Javor\u0161ek, U., Vizovi\u0161ek, M. & Turk, B. Cysteine cathepsins and their extracellular roles: shaping the microenvironment. Cells 8, 264 (2019).","journal-title":"Cells"},{"key":"2654_CR46","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1084\/jem.20011836","volume":"196","author":"KN Balaji","year":"2002","unstructured":"Balaji, K. N., Schaschke, N., Machleidt, W., Catalfamo, M. & Henkart, P. A. Surface cathepsin B protects cytotoxic lymphocytes from self-destruction after degranulation. J. Exp. Med. 196, 493\u2013503 (2002).","journal-title":"J. Exp. Med."},{"key":"2654_CR47","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1038\/nrc4027","volume":"15","author":"OC Olson","year":"2015","unstructured":"Olson, O. C. & Joyce, J. A. Cysteine cathepsin proteases: regulators of cancer progression and therapeutic response. Nat. Rev. Cancer 15, 712\u2013729 (2015).","journal-title":"Nat. Rev. Cancer"},{"key":"2654_CR48","first-page":"69","volume":"30","author":"D Gabrijelcic","year":"1992","unstructured":"Gabrijelcic, D. et al. Cathepsins B, H and L in human breast carcinoma. Eur. J. Clin. Chem. Clin. Biochem 30, 69\u201374 (1992).","journal-title":"Eur. J. Clin. Chem. Clin. Biochem"},{"key":"2654_CR49","doi-asserted-by":"publisher","first-page":"7551","DOI":"10.1021\/bi980026r","volume":"37","author":"S Estrada","year":"1998","unstructured":"Estrada, S. et al. The role of Gly-4 of human cystatin A (Stefin A) in the binding of target proteinases. characterization by kinetic and equilibrium methods of the interactions of cystatin A Gly-4 mutants with papain, cathepsin B, and cathepsin L. Biochemistry 37, 7551\u20137560 (1998).","journal-title":"Biochemistry"},{"key":"2654_CR50","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/S0014-5793(00)02337-1","volume":"487","author":"A Pavlova","year":"2000","unstructured":"Pavlova, A., Krupa, J. C., Mort, J. S., Abrahamson, M. & Bj\u00f6rk, I. Cystatin inhibition of cathepsin B requires dislocation of the proteinase occluding loop. Demonstration by release of loop anchoring through mutation of His110. FEBS Lett. 487, 156\u2013160 (2000).","journal-title":"FEBS Lett."},{"key":"2654_CR51","doi-asserted-by":"publisher","first-page":"11326","DOI":"10.1021\/bi030119v","volume":"42","author":"A Pavlova","year":"2003","unstructured":"Pavlova, A. & Bj\u00f6rk, I. Grafting of features of cystatins C or B into the N-terminal region or second binding loop of cystatin A (Stefin A) substantially enhances inhibition of cysteine proteinases. Biochemistry 42, 11326\u201311333 (2003).","journal-title":"Biochemistry"},{"key":"2654_CR52","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1016\/S0002-9440(10)63056-8","volume":"159","author":"ME Guicciardi","year":"2001","unstructured":"Guicciardi, M. E., Miyoshi, H., Bronk, S. F. & Gores, G. J. Cathepsin B knockout mice are resistant to tumor necrosis factor-\u03b1-mediated hepatocyte apoptosis and liver injury implications for therapeutic applications. Am. J. Pathol. 159, 2045\u20132054 (2001).","journal-title":"Am. J. Pathol."},{"key":"2654_CR53","doi-asserted-by":"publisher","first-page":"4191","DOI":"10.1038\/onc.2008.59","volume":"27","author":"O Vasiljeva","year":"2008","unstructured":"Vasiljeva, O. et al. Reduced tumour cell proliferation and delayed development of high-grade mammary carcinomas in cathepsin B-deficient mice. Oncogene 27, 4191\u20134199 (2008).","journal-title":"Oncogene"},{"key":"2654_CR54","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1124\/pharmrev.121.000527","volume":"74","author":"G Hook","year":"2022","unstructured":"Hook, G. et al. Cathepsin B gene knockout improves behavioral deficits and reduces pathology in models of neurologic disorders. Pharmacol. Rev. 74, 600\u2013629 (2022).","journal-title":"Pharmacol. Rev."},{"key":"2654_CR55","doi-asserted-by":"publisher","first-page":"4516","DOI":"10.1073\/pnas.95.8.4516","volume":"95","author":"J Deussing","year":"1998","unstructured":"Deussing, J. et al. Cathepsins B and D are dispensable for major histocompatibility complex class II-mediated antigen presentation. Proc. Natl. Acad. Sci. USA 95, 4516\u20134521 (1998).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2654_CR56","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1002\/prot.20041","volume":"55","author":"S Jenko","year":"2004","unstructured":"Jenko, S. et al. Different propensity to form amyloid fibrils by two homologous proteins\u2014Human stefins A and B: Searching for an explanation. Proteins 55, 417\u2013425 (2004).","journal-title":"Proteins"},{"key":"2654_CR57","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.3389\/fimmu.2019.02664","volume":"10","author":"X Xu","year":"2019","unstructured":"Xu, X. et al. Mechanisms of relapse after CD19 CAR T-cell therapy for acute lymphoblastic leukemia and its prevention and treatment strategies. Front. Immunol. 10, 2664 (2019).","journal-title":"Front. Immunol."},{"key":"2654_CR58","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1631\/jzus.B2200256","volume":"23","author":"T Gu","year":"2022","unstructured":"Gu, T., Zhu, M., Huang, H. & Hu, Y. Relapse after CAR-T cell therapy in B-cell malignancies: challenges and future approaches. J. Zhejiang Univ. Sci. B 23, 793\u2013811 (2022).","journal-title":"J. Zhejiang Univ. Sci. B"},{"key":"2654_CR59","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/j.cmet.2022.08.007","volume":"34","author":"Z Lu","year":"2022","unstructured":"Lu, Z. et al. ATF3 and CH25H regulate effector trogocytosis and anti-tumor activities of endogenous and immunotherapeutic cytotoxic T lymphocytes. Cell Metab. 34, 1342\u20131358.e7 (2022).","journal-title":"Cell Metab."},{"key":"2654_CR60","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.ado2054","volume":"10","author":"S Barbera","year":"2025","unstructured":"Barbera, S. et al. Trogocytosis of chimeric antigen receptors between T cells is regulated by their transmembrane domains. Sci. Immunol. 10, eado2054 (2025).","journal-title":"Sci. Immunol."},{"key":"2654_CR61","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1074\/mcp.M114.044404","volume":"14","author":"LL Jin","year":"2015","unstructured":"Jin, L. L. et al. Tyrosine phosphorylation of the Lyn Src homology 2 (SH2) domain modulates its binding affinity and specificity*[S]. Mol. Cell. Proteom. 14, 695\u2013706 (2015).","journal-title":"Mol. Cell. Proteom."},{"key":"2654_CR62","doi-asserted-by":"publisher","first-page":"12481","DOI":"10.1074\/jbc.271.21.12481","volume":"271","author":"DR Stover","year":"1996","unstructured":"Stover, D. R., Furet, P. & Lydon, N. B. Modulation of the SH2 binding specificity and kinase activity of src by tyrosine phosphorylation within its SH2 domain. J. Biol. Chem. 271, 12481\u201312487 (1996).","journal-title":"J. Biol. Chem."},{"key":"2654_CR63","first-page":"9","volume":"22","author":"Y Xu","year":"2005","unstructured":"Xu, Y., Harder, K. W., Huntington, N. D., Hibbs, M. L. & Tarlinton, D. M. Lyn tyrosine kinase accentuating the positive and the negative. Immunity 22, 9\u201318 (2005).","journal-title":"Immunity"},{"key":"2654_CR64","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/0014-5793(91)80319-X","volume":"280","author":"T Towatari","year":"1991","unstructured":"Towatari, T. et al. Novel epoxysuccinyl peptides A selective inhibitor of cathepsin B, in vivo. FEBS Lett. 280, 311\u2013315 (1991).","journal-title":"FEBS Lett."},{"key":"2654_CR65","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/0014-5793(91)80318-W","volume":"280","author":"M Murata","year":"1991","unstructured":"Murata, M. et al. Novel epoxysuccinyl peptides. Selective inhibitors of cathepsin B, in vitro. FEBS Lett. 280, 307\u2013310 (1991).","journal-title":"FEBS Lett."},{"key":"2654_CR66","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/0014-5793(91)80804-C","volume":"285","author":"V Turk","year":"1991","unstructured":"Turk, V. & Bode, W. The cystatins: protein inhibitors of cysteine proteinases. FEBS Lett. 285, 213\u2013219 (1991).","journal-title":"FEBS Lett."},{"key":"2654_CR67","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1016\/j.ccell.2022.11.006","volume":"40","author":"A Smole","year":"2022","unstructured":"Smole, A. et al. Expression of inducible factors reprograms CAR-T cells for enhanced function and safety. Cancer Cell 40, 1470\u20131487.e7 (2022).","journal-title":"Cancer Cell"},{"key":"2654_CR68","doi-asserted-by":"publisher","first-page":"eaba1624","DOI":"10.1126\/science.aba1624","volume":"378","author":"GM Allen","year":"2022","unstructured":"Allen, G. M. et al. Synthetic cytokine circuits that drive T cells into immune-excluded tumors. Science 378, eaba1624\u2013eaba1624 (2022).","journal-title":"Science"},{"key":"2654_CR69","doi-asserted-by":"publisher","first-page":"3660","DOI":"10.3390\/cancers12123660","volume":"12","author":"M Prunk","year":"2020","unstructured":"Prunk, M. et al. Extracellular cystatin F is internalised by cytotoxic T lymphocytes and decreases their cytotoxicity. Cancers 12, 3660 (2020).","journal-title":"Cancers"},{"key":"2654_CR70","doi-asserted-by":"publisher","first-page":"22310","DOI":"10.18632\/oncotarget.4208","volume":"6","author":"\u0160 Magister","year":"2015","unstructured":"Magister, \u0160, Tseng, H.-C., Bui, V. T., Kos, J. & Jewett, A. Regulation of split anergy in natural killer cells by inhibition of cathepsins C and H and cystatin F. Oncotarget 6, 22310\u201322327 (2015).","journal-title":"Oncotarget"},{"key":"2654_CR71","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1084\/jem.20150304","volume":"212","author":"DC Palmer","year":"2015","unstructured":"Palmer, D. C. et al. Cish actively silences TCR signaling in CD8+ T cells to maintain tumor tolerance. J. Exp. Med. 212, 2095\u20132113 (2015).","journal-title":"J. Exp. Med."},{"key":"2654_CR72","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.omto.2022.12.003","volume":"28","author":"J Lv","year":"2023","unstructured":"Lv, J. et al. Disruption of CISH promotes the antitumor activity of human T cells and decreases PD-1 expression levels. Mol. Ther. Oncolytics 28, 46\u201358 (2023).","journal-title":"Mol. Ther. Oncolytics"},{"key":"2654_CR73","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.medj.2022.07.008","volume":"3","author":"DC Palmer","year":"2022","unstructured":"Palmer, D. C. et al. Internal checkpoint regulates T cell neoantigen reactivity and susceptibility to PD1 blockade. Med 3, 682\u2013704.e8 (2022).","journal-title":"Med"},{"key":"2654_CR74","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1146\/annurev-med-062315-120245","volume":"68","author":"K Newick","year":"2016","unstructured":"Newick, K., O\u2019Brien, S., Moon, E. & Albelda, S. M. CAR T cell therapy for solid tumors. Annu. Rev. Med. 68, 139\u2013152 (2016).","journal-title":"Annu. Rev. Med."},{"key":"2654_CR75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner, R. C. & Sterner, R. M. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 11, 1\u201311 (2021).","journal-title":"Blood Cancer J."},{"key":"2654_CR76","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","volume":"385","author":"DW Lee","year":"2015","unstructured":"Lee, D. W. et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385, 517\u2013528 (2015).","journal-title":"Lancet"},{"key":"2654_CR77","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1038\/s41591-019-0549-5","volume":"25","author":"S Ghorashian","year":"2019","unstructured":"Ghorashian, S. et al. Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR. Nat. Med. 25, 1408\u20131414 (2019).","journal-title":"Nat. Med."},{"key":"2654_CR78","doi-asserted-by":"publisher","first-page":"21533","DOI":"10.18632\/oncotarget.4071","volume":"6","author":"D-G Song","year":"2015","unstructured":"Song, D.-G. et al. A fully human chimeric antigen receptor with potent activity against cancer cells but reduced risk for off-tumor toxicity. Oncotarget 6, 21533\u201321546 (2015).","journal-title":"Oncotarget"},{"key":"2654_CR79","unstructured":"World Health Organization. INN Database https:\/\/extranet.who.int\/soinn\/ (2026)."},{"key":"2654_CR80","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1158\/2326-6066.CIR-17-0211","volume":"6","author":"SA Richman","year":"2018","unstructured":"Richman, S. A. et al. High-affinity GD2-specific CAR T cells induce fatal encephalitis in a preclinical neuroblastoma model. Cancer Immunol. Res. 6, 36\u201346 (2018).","journal-title":"Cancer Immunol. Res."},{"key":"2654_CR81","doi-asserted-by":"publisher","first-page":"e31457","DOI":"10.1371\/journal.pone.0031457","volume":"7","author":"SL Veatch","year":"2012","unstructured":"Veatch, S. L. et al. Correlation functions quantify super-resolution images and estimate apparent clustering due to over-counting. PLoS One 7, e31457 (2012).","journal-title":"PLoS One"},{"key":"2654_CR82","doi-asserted-by":"publisher","first-page":"25764","DOI":"10.18632\/oncotarget.25359","volume":"9","author":"D-X Bu","year":"2018","unstructured":"Bu, D.-X. et al. Pre-clinical validation of B cell maturation antigen (BCMA) as a target for T cell immunotherapy of multiple myeloma. Oncotarget 9, 25764\u201325780 (2018).","journal-title":"Oncotarget"}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02654-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02654-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02654-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T19:02:09Z","timestamp":1776884529000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02654-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":82,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2654"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02654-z","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,22]]},"assertion":[{"value":"30 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.A.D. and T.L. are inventors on patent application number PCT\/US24\/53867 describing therapeutic targeting of tumor escape by CMT. T.L. received a salary from AbbVie. The other authors are not declaring any conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"149"}}